A Peptide Inhibitor of FOXP3 Impairs Regulatory T Cell Activity and Improves Vaccine Efficacy in Mice
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Immunosuppressive activity of regulatory T cells (Treg) may contribute to the progression of cancer or infectious diseases by preventing the induction of specific immune responses. Using a phage-displayed random peptide library, we identified a 15-mer synthetic peptide, P60, able to bind to forkhead/winged helix transcription factor 3 (FOXP3), a factor required for development and function of Treg. P60 enters the cells, inhibits FOXP3 nuclear translocation, and reduces its ability to suppress the transcription factors NF-κB and NFAT. In vitro, P60 inhibited murine and human-derived Treg and improved effector T cell stimulation. P60 administration to newborn mice induced a lymphoproliferative autoimmune syndrome resembling the reported pathology in scurfy mice lacking functional Foxp3. However, P60 did not cause toxic effects in adult mice and, when given to BALB/c mice immunized with the cytotoxic T cell epitope AH1 from CT26 tumor cells, it induced protection against tumor implantation. Similarly, P60 improved the antiviral efficacy of a recombinant adenovirus expressing NS3 protein from hepatitis C virus. Functional inhibition of Treg by the FOXP3-inhibitory peptide P60 constitutes a strategy to enhance antitumor and antiviral immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151 · cited 1×
“Indeed, Tregs capable of suppressing the in vitro function of tumor-reactive T cells have been found in humans in many types of tumors (9–13) and have been associated with a high death hazard and reduced survival (9, 11).”
BackgroundShimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Transient expression of FOXP3 in human activated nonregulatory CD4 + T cells
Wang, J., Ioan‐Facsinay, A., van der Voort, E. I. H., Huizinga, T. W. J., & Toes, R. E. M. (2007) · European Journal of Immunology · doi:10.1002/eji.200636435 · Cited by 1,011 · cited 2×
“It has been described that anti-CD3 stimulation of human effector CD4 T cells induced a transient upregulation of FOXP3 that, although it did not confer immunosuppressive activity to the T cell, was strongly associated with hyporesponsiveness of activated T cells to subsequent stimulation (36).”
Background
Cited by
Neoantigen vaccine: an emerging tumor immunotherapy
Peng, M., Mo, Y., Wang, Y., Wu, P., Zhang, Y., Xiong, F., Guo, C., Wu, X., Li, Y., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1055-6 · Cited by 700
The dark side of Tregs during aging
Palatella, M., Guillaume, S. M., Linterman, M. A., & Huehn, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940705 · Cited by 58
Transcriptional Control of Regulatory T cells
Delacher, M., Schreiber, L., Richards, D. M., Farah, C., Feuerer, M., & Huehn, J. (2014) · Current Topics in Microbiology and Immunology · doi:10.1007/82_2014_373 · Cited by 19
Milk Derived Peptides with Immune Stimulating Antiviral Properties
Sun, H., & Jensse, H. (2012) · Milk Protein · doi:10.5772/50158 · Cited by 12
Metadata
- Authors
- Casares, N., Rudilla, F., Arribillaga, L., Llopiz, D., Riezu-Boj, J. I., Lozano, T., López-Sagaseta, J., Guembe, L., Sarobe, P., Prieto, J., Borrás-Cuesta, F., & Lasarte, J. J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-11-01
- Volume
- 185
- Issue
- 9
- Pages
- 5150-5159
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2167050845
- Cited by
- 124
- References
- 3
- FWCI
- 1.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.